
(IN BRIEF) Sanofi has agreed to acquire Provention Bio, a U.S.-based biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, for $2.9 billion. The acquisition includes Provention Bio’s first-in-class therapy for type 1 diabetes, TZIELD, which was approved in the … Read the full press release